Lung cancer drug poised for global approval, says MWC investigator
11 December 2017
Dacomitinib, an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed in collaboration with Pfizer by researchers led by MWC Associate Investigator Dr. Jeff Smaill, has shown significant efficacy in the treatment of patients with non-small-...
Dr Aniruddha Chatterjee awarded Rutherford Discovery Fellowship
13 October 2017
MWC Affiliate Investigator Dr Aniruddha Chatterjee of the University of Otago is one of only ten recipients across the country to be awarded a 2017 Rutherford Discovery Fellowship.